LC-MS/MS Ratio Analysis for CBD and THC Metabolite Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug testing methodologies face challenges in distinguishing cannabidiol (CBD) use from tetrahydrocannabinol (THC) use due to their structural similarity, leading to false positives and contamination issues with unregulated CBD products, which complicates urine drug screens and requires accurate differentiation for workplace and medical monitoring.
Innovation Solution
The method involves measuring CBD and its metabolites alongside THC and its metabolites using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) to compare their ratios in biological samples, allowing for discrimination between CBD and THC use by determining the relative levels and metabolic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional GC or LC techniques are used to detect THC metabolites, then the detection capability is sufficient for THC, but the ability to discriminate CBD metabolites from THC metabolites deteriorates due to their structural similarity
Solution Approach 1:
The patent changes the detection parameters by using tandem mass spectrometry with multiple reaction monitoring (MRM) to measure specific mass-to-charge ratios and fragmentation patterns. This allows differentiation of CBD and THC metabolites based on their unique mass spectrometric parameters rather than relying on chromatographic separation alone, thereby improving discrimination accuracy while managing complexity through targeted parameter measurement.
2Reliability
If older GC-MS techniques are used for THC analysis, then the detection of THC is achieved, but CBD is inappropriately converted into THC leading to false positives
Solution Approach 1:
The patent introduces an intermediary measurement approach by quantifying both CBD metabolites (such as 7-carboxycannabidiol or COO-CBD) and THC metabolites (such as 11-carboxy-Δ9-tetrahydrocannabinol or COO-THC) separately using tandem mass spectrometry. This intermediary measurement of CBD metabolites allows differentiation between actual THC use and CBD use with THC contamination, eliminating false positives while maintaining reliable detection of marijuana use.
3Quantity of substance
If unregulated CBD products are tested using conventional methods, then the presence of CBD is detected, but coincidental THC contamination cannot be distinguished from actual marijuana use
Solution Approach 1:
The patent implements a feedback mechanism by calculating and evaluating the ratio of CBD metabolites to THC metabolites. This feedback ratio provides critical information about the source of detected substances: a high CBD:THC ratio indicates CBD product use with contamination, while a low ratio indicates direct marijuana use. This quantitative feedback allows laboratories to interpret results in context and distinguish between different sources of cannabinoid exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively differentiates CBD use from THC use, reducing false positives and accurately identifying CBD users without THC exposure, even in cases of contamination, thereby enhancing the specificity and sensitivity of drug testing.
Implementation Method 1
The method may comprise a method to measure relative levels of CBD and/or THC or metabolites of CBD and/or THC in a biological sample
Implementation Method 2
In certain embodiments, the method is performed using LC-MS/MS. For example, in certain embodiments, the method may comprise a method to measure relative levels of CBD and/or THC or metabolites of CBD and/or THC in a biological sample comprising the steps of: (a) obtaining MS/MS data comprising a predetermined MS/MS transition for THC and/or at least one THC metabolite and CBD and/or at least one CBD metabolite
Data Source
AI summary
The methods and systems may include LC-MS/MS. For example the method may include obtaining MS/MS data for a predetermined MS/MS transition for THC and/or at least one THC metabolite and CBD and/or at least one CBD metabolite, and determining a ratio of the amount of the CBD and/or at least one CBD metabolite to the amount of the THC and/or at least one THC metabolite for the biological sample. In certain embodiments, the methods and/or systems are used to distinguish CBD from THC use in a subject.